BIRC5 and non-small cell lung carcinoma: In another Phase I/IIa clinical trial (NCT00923312), 7 patients with locally advanced disease and 39 patients with metastatic NSCLC were treated with 5 doses of intradermal injection of CV9201, an active vaccine encoding 5 antigens including NY-ESO-1, MAGE-C1/2, survivin, trophoblast glycoprotein and 5T4 (41).